62 results about "Immune status" patented technology

Compositions containing clinically relevant numbers of immune cells that have been isolated from a patient differentiated and/or expanded ex vivo. Methods for treating or preventing disease or otherwise altering the immune status of the patient by reinfusing such cells into the donor are also provided. Methods for expanding and/or immune cells, including effector cells, in the absence of exogenous IL-2, and for administering the cells in the absence of co-infused IL-2 are also provided.

Compositions containing clinically relevant numbers of immune cells that have been isolated from a patient differentiated and/or expanded ex vivo. Methods for treating or preventing disease or otherwise altering the immune status of the patient by reinfusing such cells into the donor are also provided. Methods for expanding and/or immune cells, including effector cells, in the absence of exogenous IL-2, and for administering the cells in the absence of co-infused IL-2 are also provided.

The present inventions are directed to apparatuses for rapidly measuring post-vaccination immune status. In one version, the apparatus has a support platform, with a top side, a bottom side, a first portion, and a second portion. A first void is integrally formed in the first portion. A container is configured to be removably affixed to the top side of the support platform. The container has a housing, a base, and at least one reactant. The container base can be viewed through the first void when the container is removably affixed to the first portion of the top side. An absorbent material is affixed to the second portion, where the base of the container comes into contact with the absorbent material when the container is removably affixed to the second portion of the top side.

A composition which elicits antibodies to multiple known variants of Tat protein of HIV-1 of both the B and non-B clades contains the peptide R1-Asp-Pro-Asn-Leu-Asp-Pro-Trp-Asn-R2 SEQ ID NO: 23, and preferably an additional at least two variants of a peptide or polypeptide of the formula: R1-Asp-Pro-Y₇-Leu-X₉-Pro-Trp-Z₁₂-R2 (SEQ ID NO: 8). In this composition, at least one of the two variants contains Arg at Y₇ and Lys at Z₁₂, and in at least a second of the two variants Y₇ is Asn and Z₁₂ is Asn. Vaccinal and pharmaceutical compositions can contain one or more such peptides associated with carrier proteins, associated in multiple antigenic peptides or as part of recombinant proteins. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients.

A method for the discovery, development and clinical application of multidimensional multiplex synthetic biomarker assays based on patterns of cellular response.

After stimulation or inhibition, a selected multiplicity of cell types are assayed for a multiplicity of cellular or molecular responses, and known machine learning techniques are used to synthesize the cellular responses into an optimized clinical biomarker. The computationally derived algorithm includes the relationships within and between the component steps so as to produce an optimized synthetic clinical biomarker. During discover of the assay one or more of the component steps are repeated iteratively until a final clinically optimized algorithm is produced.

Such a multidimensional multiplex cell response assay may provide improved diagnostic performance with respect to entities such as immune status, infection, and antibiotic and vaccine efficacy, among others.

A semi-quantitative, immunochromatographic device for the detection of HIV/AIDS immune status CD4+ T cell equivalents, such as soluble CD40 ligand/CD 154, includes one or more support materials capable of providing lateral flow. The one or more support materials include a first area for receiving a biological sample containing a target analyte, the analyte being a CD4+ T cell equivalent, such as soluble CD40 ligand/CD 154, a second area having a movably contained detector ligand, wherein the detector ligand is capable of forming a mobile complex with the soluble CD40 ligand/CD 154, and at least one capture area having a predetermined amount of an immobile capture reagent, the immobile capture reagent capable of specifically binding to the mobile complex formed by the soluble CD40 ligand/CD 154 protein and the detector ligand and providing a visible signal.

A semi-quantitative, immunochromatographic dual test device for the simultaneous detection of HIV/AIDS immune status CD4+ T cell equivalents, such as soluble CD40 ligand/CD 154, and the detection of an HIV antibody, includes one or more support materials capable of providing lateral flow. The one or more support materials include at least one sample receiving area for receiving a biological sample containing a first target analyte, the first target analyte being a CD4+ T cell equivalent, such as soluble CD40 ligand/CD 154, and a second target analyte, the second target analyte being an HIV antibody. A second area, situated on the one or more support materials, has a movably contained detector ligand and or detector antigens, wherein the detector ligand and or detector antigens is capable of forming a mobile complex with the soluble CD40 ligand/CD 154 and or HIV antibodies, and at least a first capture area having a predetermined amount of a first immobile capture reagent, the first immobile capture reagent capable of specifically binding to the mobile complex formed by the soluble CD40 ligand/CD 154 protein and the detector ligand and providing a visible signal. The one or more support materials further have situated thereon at least a second capture area having a predetermined amount of a second immobile capture reagent that is capable of specifically binding to HIV antibodies present in the biological sample and providing a visible signal.

The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses.

Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.

Provided is a method and a kit for testing the immune status of patients with chronic inflammatory diseases by measuring the TCR zeta chain (CD247) expression levels, and in particular a method and a kit for testing the selective downregulation of TCR zeta chain expression in T cells, NK cells, or NKT cells of such patients. Zeta chain expression is measured using antibodies directed against the intracellular zeta chain region, and these levels are compared with the expression levels of other T cell receptor subunits and NK cell markers. Thus, a kit for diagnosis, prognosis, and monitoring the immune status, of patients with chronic inflammatory diseases is presented herein.

The invention discloses an ELISA detection method for a canine distemper virus and antibody. A canine distemper virus N protein is used to make a canine distemper detection kit, and the amino acid sequence is shown in SEQ ID NO:1. The canine distemper virus N protein is only used as an antibody to build the ELISA detection method, the N protein has good antigenicity as a canine distemper virus conserved protein and can quantify anti-canine distemper virus antibodies in a serum sample on the premise of preventing virus spread, the immune status of a blood-derived organism for the canine distemper virus or the immune level of the canine distemper virus secreted by a cell can be detected, more safety and higher efficiency are achieved compared with other products, and positive meaning is achieved for basic research and clinical detection on the canine distemper virus.

The invention discloses a multi-functional aquatic feed additive. The multi-functional aquatic feed additive comprises the following raw materials in parts by weight: 5-15 parts of radix astragali, 10-20 parts of scutellaria lateriflora, 10-14 parts of radix codonopsis, 6-8 parts of caulis spatholobi, 3-7 parts of honeysuckle flowers, 3-5 parts of rheum officinale, 2-3 parts of taurine, 2-4 parts of biologically active peptides, 1-2 parts of probiotics, 3-5 parts of prebiotics, 0.1-1 part of malathion, 4-8 parts of rapeseed cakes, 20-30 parts of food processing wastes, and 2-3 parts of a biologically active bacterial agent. The multi-functional aquatic feed additive disclosed by the invention has advantages of both Chinese herbal medicines and the probiotics. The multi-functional aquatic feed additive is capable of efficiently conditioning intestinal health of aquatic animals, maintaining micro-ecological balance and optimal immune status of the intestinal track, increasing digestion and absorption rates to nutrients, enhancing immunity of animal bodies, improving aquaculture yields and reducing aquaculture risks; moreover, the multi-functional aquatic feed additive can be used instead of antibiotics, and is free of adverse effects on the aquatic animals, safe to use, and free of problems, such as drug residues, drug resistance and so on. In addition, a preparation method of the multi-functional aquatic feed additive provided by the invention is relatively low in material cost, easy in raw materials obtaining and simple in processes, and thus, the preparation method thereof has good application prospects.

The invention discloses an immune mouse model with pulmonary delivery of liquid aerosol of a Yersinia pestis F1 vaccine. The invention provides a method for preparing an animal model. The method for preparing the animal model comprises the following steps: delivering immunogen to lungs of animals by the means of liquid aerosols; and then, carrying out challenging by using pathogen corresponding tothe immunogen so as to obtain the animal model. According to the method for preparing the animal model, tested substances are directly delivered to lungs of mice by the means of liquid aerosols so asto construct a novel immune mouse model; and the constructed model is highly targeted, good in repeatability, and capable of allowing accurate and quantitative study of immune status of the tested substances in mice.

A method of detecting the presence of a functionally inhibitory immunointeractive molecule in a biological sample. Preferably, the immunointeractive molecule is directed to a pathogen derived antigen and, more particularly, a parasite derived antigen and, even more particularly, a Plasmodium drived antigen. The method of the present invention facilitates detection of the presence of functionally inhibitory immunointeractive molecules, both in vitro and in vivo, and is useful for qualitatively and/or quantitatively assessing the immune status of individuals who have been previously infected with a parasite, predicting the immune status of individuals vaccinated with an antigen based vaccine, determining the relative contribution of a specific immunoreactivity of antibody to the total inhibitory antibody elicited by combination vaccines which include two or more antigens, assessing vaccines to determine the efficacy of different forms of an antigen, determining vaccine potency, assessing the protective potential of certain immunoreactivities of antibodies and determining the importance of parasite inhibitory antibodies.